165 related articles for article (PubMed ID: 32218835)
21. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
[TBL] [Abstract][Full Text] [Related]
22. Integrative analysis identifies cancer cell-intrinsic RARRES1 as a predictor of prognosis and immune response in triple-negative breast cancer.
Yu Z; Liu H; Ye J; Liu Y; Xin L; Liu Q; Cheng Y; Yin L; Xu L
Front Genet; 2024; 15():1360507. PubMed ID: 38533207
[TBL] [Abstract][Full Text] [Related]
23. Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.
Oshi M; Kawaguchi T; Yan L; Peng X; Qi Q; Tian W; Schulze A; McDonald KA; Narayanan S; Young J; Liu S; Morris LG; Chan TA; Kalinski P; Matsuyama R; Otsuji E; Endo I; Takabe K
Am J Cancer Res; 2021; 11(7):3628-3644. PubMed ID: 34354864
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes based on multigene profiling in metastatic breast cancer patients.
Basho RK; de Melo Gagliato D; Ueno NT; Wathoo C; Chen H; Shariati M; Wei C; Alvarez RH; Moulder SL; Sahin AA; Roy-Chowdhuri S; Chavez-MacGregor M; Litton JK; Valero V; Luthra R; Zeng J; Shaw KR; Mendelsohn J; Mills GB; Tripathy D; Meric-Bernstam F
Oncotarget; 2016 Nov; 7(47):76362-76373. PubMed ID: 27806348
[TBL] [Abstract][Full Text] [Related]
25. Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors.
Naik A; Decock J
Front Oncol; 2020; 10():598626. PubMed ID: 33324565
[TBL] [Abstract][Full Text] [Related]
26. Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers.
Lv Y; Lv D; Lv X; Xing P; Zhang J; Zhang Y
Front Genet; 2021; 12():616469. PubMed ID: 33815462
[TBL] [Abstract][Full Text] [Related]
27. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
28. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
[TBL] [Abstract][Full Text] [Related]
30. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
31. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Sharma P
Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for metastatic breast cancer.
Sugie T
Chin Clin Oncol; 2018 Jun; 7(3):28. PubMed ID: 30056730
[TBL] [Abstract][Full Text] [Related]
33. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
34. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
35. Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.
Xu J; Bao H; Wu X; Wang X; Shao YW; Sun T
Oncol Lett; 2019 Jul; 18(1):449-455. PubMed ID: 31289516
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Joneja U; Vranic S; Swensen J; Feldman R; Chen W; Kimbrough J; Xiao N; Reddy S; Palazzo J; Gatalica Z
J Clin Pathol; 2017 Mar; 70(3):255-259. PubMed ID: 27531819
[TBL] [Abstract][Full Text] [Related]
37. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Munzone E; Gray KP; Fumagalli C; Guerini-Rocco E; Láng I; Ruhstaller T; Gianni L; Kammler R; Viale G; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Barberis M; Colleoni M
Breast Cancer Res Treat; 2018 Jul; 170(2):351-360. PubMed ID: 29589138
[TBL] [Abstract][Full Text] [Related]
38. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
[TBL] [Abstract][Full Text] [Related]
39. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.
Bourgeois-Daigneault MC; Roy DG; Aitken AS; El Sayes N; Martin NT; Varette O; Falls T; St-Germain LE; Pelin A; Lichty BD; Stojdl DF; Ungerechts G; Diallo JS; Bell JC
Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]